Company intelligence / Profile preview

Fosun International

Shanghai, Shanghai, China

Ownership: Private
Employees: ~40557
Development stage: Other

Overview

As of 2024, Fosun International (primarily through Fosun Pharma) has over 80 active major pipeline projects, with 16 indications for 7 innovative drugs/biosimilars approved in 2024, a strong presence in biosimilars (trastuzumab, rituximab), innovative antibodies, CAR-T cell therapy for lymphomas, and COVID-19 mRNA vaccines through BioNTech partnership; achieved commercial scale, including China, US, EU, and African markets, with numerous assets in late-stage and approved status[1][2][3][4].

Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateBiosimilarVaccineCell therapymRNA-based drugs
Industry: Pharma

Partnerships

Gilead (Kite Pharma, CAR-T)BioNTech (COVID-19 vaccine)Amgen (Otezla, Parsabiv)AbbottOrganonGSK

Beyond the preview

Go deeper on Fosun International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fosun International.

Explore the full profile